These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33081784)

  • 1. Global estimation of anti-malarial drug effectiveness for the treatment of uncomplicated Plasmodium falciparum malaria 1991-2019.
    Rathmes G; Rumisha SF; Lucas TCD; Twohig KA; Python A; Nguyen M; Nandi AK; Keddie SH; Collins EL; Rozier JA; Gibson HS; Chestnutt EG; Battle KE; Humphreys GS; Amratia P; Arambepola R; Bertozzi-Villa A; Hancock P; Millar JJ; Symons TL; Bhatt S; Cameron E; Guerin PJ; Gething PW; Weiss DJ
    Malar J; 2020 Oct; 19(1):374. PubMed ID: 33081784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deployment and utilization of next-generation sequencing of Plasmodium falciparum to guide anti-malarial drug policy decisions in sub-Saharan Africa: opportunities and challenges.
    Ishengoma DS; Saidi Q; Sibley CH; Roper C; Alifrangis M
    Malar J; 2019 Sep; 18(1):267. PubMed ID: 31477109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local emergence in Amazonia of
    Mathieu LC; Cox H; Early AM; Mok S; Lazrek Y; Paquet JC; Ade MP; Lucchi NW; Grant Q; Udhayakumar V; Alexandre JS; Demar M; Ringwald P; Neafsey DE; Fidock DA; Musset L
    Elife; 2020 May; 9():. PubMed ID: 32394893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
    van der Pluijm RW; Tripura R; Hoglund RM; Pyae Phyo A; Lek D; Ul Islam A; Anvikar AR; Satpathi P; Satpathi S; Behera PK; Tripura A; Baidya S; Onyamboko M; Chau NH; Sovann Y; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Chutasmit K; Saelow C; Runcharern R; Kaewmok W; Hoa NT; Thanh NV; Hanboonkunupakarn B; Callery JJ; Mohanty AK; Heaton J; Thant M; Gantait K; Ghosh T; Amato R; Pearson RD; Jacob CG; Gonçalves S; Mukaka M; Waithira N; Woodrow CJ; Grobusch MP; van Vugt M; Fairhurst RM; Cheah PY; Peto TJ; von Seidlein L; Dhorda M; Maude RJ; Winterberg M; Thuy-Nhien NT; Kwiatkowski DP; Imwong M; Jittamala P; Lin K; Hlaing TM; Chotivanich K; Huy R; Fanello C; Ashley E; Mayxay M; Newton PN; Hien TT; Valecha N; Smithuis F; Pukrittayakamee S; Faiz A; Miotto O; Tarning J; Day NPJ; White NJ; Dondorp AM;
    Lancet; 2020 Apr; 395(10233):1345-1360. PubMed ID: 32171078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular surveillance of Plasmodium falciparum drug resistance in the Republic of Congo: four and nine years after the introduction of artemisinin-based combination therapy.
    Koukouikila-Koussounda F; Jeyaraj S; Nguetse CN; Nkonganyi CN; Kokou KC; Etoka-Beka MK; Ntoumi F; Velavan TP
    Malar J; 2017 Apr; 16(1):155. PubMed ID: 28420403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Artemisinin derivatives and malaria: useful, in combination with other antimalarials.
    Prescrire Int; 2008 Aug; 17(96):162-8. PubMed ID: 19492494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms of the artemisinin resistant marker (K13) in Plasmodium falciparum parasite populations of Grande Comore Island 10 years after artemisinin combination therapy.
    Huang B; Deng C; Yang T; Xue L; Wang Q; Huang S; Su XZ; Liu Y; Zheng S; Guan Y; Xu Q; Zhou J; Yuan J; Bacar A; Abdallah KS; Attoumane R; Mliva AM; Zhong Y; Lu F; Song J
    Parasit Vectors; 2015 Dec; 8():634. PubMed ID: 26667053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania.
    Kakolwa MA; Mahende MK; Ishengoma DS; Mandara CI; Ngasala B; Kamugisha E; Kataraihya JB; Mandike R; Mkude S; Chacky F; Njau R; Premji Z; Lemnge MM; Warsame M; Menard D; Kabanywanyi AM
    Malar J; 2018 Oct; 17(1):369. PubMed ID: 30333022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artemisinin-Resistant Plasmodium falciparum Malaria.
    Fairhurst RM; Dondorp AM
    Microbiol Spectr; 2016 Jun; 4(3):. PubMed ID: 27337450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primaquine for reducing Plasmodium falciparum transmission.
    Graves PM; Gelband H; Garner P
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008152. PubMed ID: 22972117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations.
    Tindana P; de Haan F; Amaratunga C; Dhorda M; van der Pluijm RW; Dondorp AM; Cheah PY
    Malar J; 2021 Feb; 20(1):119. PubMed ID: 33639946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria.
    Isba R; Zani B; Gathu M; Sinclair D
    Cochrane Database Syst Rev; 2015 Feb; 2015(2):CD011547. PubMed ID: 25702785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination.
    Ouji M; Augereau JM; Paloque L; Benoit-Vical F
    Parasite; 2018; 25():24. PubMed ID: 29676250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea.
    Tavul L; Hetzel MW; Teliki A; Walsh D; Kiniboro B; Rare L; Pulford J; Siba PM; Karl S; Makita L; Robinson L; Kattenberg JH; Laman M; Oswyn G; Mueller I
    Malar J; 2018 Oct; 17(1):350. PubMed ID: 30290825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined antimalarial therapy using artemisinin].
    Majori G
    Parassitologia; 2004 Jun; 46(1-2):85-7. PubMed ID: 15305693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How genomics is contributing to the fight against artemisinin-resistant malaria parasites.
    Cravo P; Napolitano H; Culleton R
    Acta Trop; 2015 Aug; 148():1-7. PubMed ID: 25910626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UK malaria treatment guidelines 2016.
    Lalloo DG; Shingadia D; Bell DJ; Beeching NJ; Whitty CJM; Chiodini PL;
    J Infect; 2016 Jun; 72(6):635-649. PubMed ID: 26880088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliance with a three-day course of artesunate-mefloquine combination and baseline anti-malarial treatment in an area of Thailand with highly multidrug resistant falciparum malaria.
    Congpuong K; Bualombai P; Banmairuroi V; Na-Bangchang K
    Malar J; 2010 Feb; 9():43. PubMed ID: 20132537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine-tolerance molecular markers following 18 years of artemisinin-based combination therapy use in Mpumalanga Province, South Africa (2001-2018).
    Raman J; Kagoro FM; Mabuza A; Malatje G; Reid A; Frean J; Barnes KI
    Malar J; 2019 Aug; 18(1):280. PubMed ID: 31438951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.